Intervention not reported
Improvement in acne severity assessed by a decrease in total inflammatory lesion count, measured in participants who were treated for a minimum period of 16 weeks (Changes from baseline in total inflammatory lesion count and number of participants... · participants with moderate and severe acne
1 finding from 1 review
Intervention not reported
Frequency of serious adverse effects 20 to 24 weeks · participants with moderate and severe acne
It is very uncertain whether the intervention changes frequency of serious adverse effects 20 to 24 weeks (very low certainty).
1 finding from 1 review
Intervention not reported
Improvement in acne severity assessed by physician's global evaluation 20 to 24 weeks · participants with moderate and severe acne
1 finding from 1 review
Participant's global assessment of improvement Non‐standardised scale5 · Mild, moderate and severe acne vulgaris
1 finding from 1 review
Investigator's global assessment (IGA) of improvement Treatment 'success' as defined by IGA score decrease5 · Moderate and severe acne vulgaris
MAL‐PDT probably leads to higher investigator's global assessment (IGA) of improvement Treatment… compared with red light only (moderate certainty).
1 finding from 1 review
Participant's global assessment of improvement Non‐standardised scale5 · Moderate and severe acne vulgaris
ALA‐PDT showed no clear difference in participant's global assessment of improvement Non‐standardised scale5 compared with blue light only (low certainty).
1 finding from 1 review
Investigator‐assessed change in inflamed lesions (ILs) Lesion counts · Moderate and severe acne vulgaris
1 finding from 1 review
Investigator‐assessed percentage change in ILs Lesion counts · Moderate and severe acne vulgaris
1 finding from 1 review
Investigator‐assessed severe adverse effects Application site blister · Moderate and severe acne vulgaris
1 finding from 1 review
Investigator's global assessment (IGA) of improvement Treatment 'success' as defined by IGA score decrease5 · Moderate and severe acne vulgaris
ALA‐PDT showed no clear difference in investigator's global assessment (IGA) of improvement Treatment… compared with blue light only (low certainty).
1 finding from 1 review
Lesion count · Mild, moderate and severe acne vulgaris
1 finding from 1 review
Investigator‐assessed severe adverse effects Blistering or scarring · Mild, moderate and severe acne vulgaris
1 finding from 1 review
Paticipant's global assessment of improvement ‐ Not measured · Moderate and severe acne vulgaris
The review found no eligible studies for this question.
1 finding from 1 review
Light therapies for acne 2016 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Investigator‐assessed change in inflamed lesions (ILs) Lesion counts · Moderate and severe acne vulgaris
1 finding from 1 review
Investigator‐assessed change in non‐inflamed lesions (NILs) Lesion counts · Moderate and severe acne vulgaris
1 finding from 1 review
Investigator‐assessed percentage change in ILs Lesion counts · Moderate and severe acne vulgaris
1 finding from 1 review
Investigator‐assessed percentage change in NILs Lesion counts · Moderate and severe acne vulgaris
1 finding from 1 review
Investigator‐assessed severe adverse effects Application site blister · Moderate and severe acne vulgaris
1 finding from 1 review
Mycological cure · patients with tinea cruris and tinea corporis
Azoles showed no clear difference in mycological cure Negative KOH microscopy and culture. Treatment… compared with moderate‐potent corticosteroid/azole combinations (low certainty).
1 finding from 1 review
Clinical cure · patients with tinea cruris and tinea corporis
It is very uncertain whether azoles changes clinical cure (immediately at end of treatment) Resolution of… compared with moderate‐potent corticosteroid/azole combinations (very low certainty).
1 finding from 1 review